Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Mediterranean Diet and Gut Microbiota in Children With Systemic Lupus Erythematosus

NCT07555626 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-06
Last updated
2026-04-29

Condition(s) studied

Systemic Lupus Erythematosus (SLE)

Investigational drug(s) / intervention(s)

Mediterranean Diet-Based Individual Nutrition Counseling

Mediterranean Diet-Based Individual Nutrition Counseling: Participants receive individualized nutrition counseling from a dietitian at Erciyes University Children Hospital, tailored to each participant. The program aims to improve adherence to the Mediterranean Diet, increase polyphenol intake, reduce the dietary inflammatory index(DII), and limit ultra-processed foods. Diet is assessed via 3-day food records and KIDMED(Mediterranean Diet Quality Index for children and adolescents) scores. Guidance is provided to improve dietary mistakes and increase physical activity(IPAQ, International Physical Activity Questionnaire). Weekly follow-ups monitor adherence. Additional assessments include stool samples, anthropometrics, PSQI (Pittsburgh Sleep Quality Index), CHAQ(Childhood Health Assessment Questionnaire), SLEDAI-2K(Systemic Lupus Erythematosus Disease Activity Index 2000), and SLICC/SDI(Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index). No food is provided; focus is on modifying existing habits.

Study summary

The goal of this clinical trial is to learn if a Mediterranean diet can improve gut microbiota, disease activity, and nutrition in children with systemic lupus erythematosus (SLE). The study will include children with SLE and healthy family members living in the same home.

The main questions it aims to answer are:

Does a Mediterranean diet improve gut microbiota in children with SLE? Does the diet help reduce disease activity? Does the diet improve overall nutrition? Researchers will compare children with SLE to healthy family members to better understand how diet, gut microbiota, and health are related.

Participants will:

Give stool samples at the beginning and end of the study to analyze gut microbiota.

Have body measurements taken. Record what they eat for 3 days (2 weekdays and 1 weekend day). Answer questions about their diet, physical activity, sleep, and health. Children with SLE in the intervention group will receive nutrition counseling based on the Mediterranean diet for 12 weeks. The counseling will focus on increasing foods rich in polyphenols and reducing processed foods to improve overall diet quality. They will also receive advice on physical activity.

At the end of the study, some participants will join a group discussion to share their experiences.

Eligibility

Sex
ALL
Min age
8 Years
Max age
18 Years
Healthy volunteers
Accepted
Inclusion Criteria: For participants with Systemic Lupus Erythematosus (SLE): * Diagnosis of SLE according to the SLICC classification criteria. * SLE diagnosis established at least 6 months prior to enrollment. For healthy controls (household members): * Living in the same household as participants with SLE. * Body mass index (BMI) within the normal range. Exclusion Criteria: For participants with SLE: * Presence of active infection. * Renal failure, or history of major trauma or surgery within the past 6 months. * Presence of additional chronic diseases other than SLE. * Use of antibiotics or probiotics within the past 4 weeks. * Following a specific or restrictive diet. * Illiteracy or cognitive impairment that may limit understanding of the intervention. For healthy controls (household members): * Presence of active infection * Presence of any chronic disease * Use of antibiotics or probiotics within the past 4 weeks * Following a specific or restrictive diet * Illiteracy or cognitive impairment that may limit understanding of study procedures

Primary outcome measure(s)

  • Gut microbiota diversity — Baseline (Week 0) and Week 12
    Changes in gut microbiota diversity assessed by 16S rRNA sequencing of stool samples.
  • Change in Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Score — Baseline and week 12
    The SLEDAI-2K evaluates overall disease activity in children with systemic lupus erythematosus over the past 10 days. It includes 24 clinical and laboratory items across nine organ systems. Scores range from 0 to 105, with scores ≥6 indicating clinically significant disease activity. Assessment is conducted at baseline and at the final study visit.

Trial sites (1)

FacilityCityRegionStatus
Erciyes University Mustafa Eraslan and Fevzi Mercan Children's Hospital Kayseri Melikgazi
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07555626 on ClinicalTrials.gov ↗ ← All trials in Turkey